- Home
- PL vs AUPH Comparison
PL vs AUPH Comparison
Compare PL & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PL
- AUPH
- Stock Information
- Founded
- PL 2010
- AUPH 1993
- Country
- PL United States
- AUPH Canada
- Employees
- PL N/A
- AUPH N/A
- Industry
- PL Aerospace
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- PL Industrials
- AUPH Health Care
- Exchange
- PL Nasdaq
- AUPH Nasdaq
- Market Cap
- PL 947.7M
- AUPH 999.8M
- IPO Year
- PL N/A
- AUPH 1999
- Fundamental
- Price
- PL $3.56
- AUPH $8.00
- Analyst Decision
- PL Buy
- AUPH Strong Buy
- Analyst Count
- PL 11
- AUPH 2
- Target Price
- PL $5.53
- AUPH $11.50
- AVG Volume (30 Days)
- PL 3.0M
- AUPH 1.0M
- Earning Date
- PL 06-04-2025
- AUPH 05-12-2025
- Dividend Yield
- PL N/A
- AUPH N/A
- EPS Growth
- PL N/A
- AUPH N/A
- EPS
- PL N/A
- AUPH 0.04
- Revenue
- PL $244,352,000.00
- AUPH $235,133,000.00
- Revenue This Year
- PL $14.08
- AUPH $11.86
- Revenue Next Year
- PL $21.49
- AUPH $24.96
- P/E Ratio
- PL N/A
- AUPH $200.00
- Revenue Growth
- PL 10.72
- AUPH 33.97
- 52 Week Low
- PL $1.67
- AUPH $4.98
- 52 Week High
- PL $6.71
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- PL 52.59
- AUPH 48.76
- Support Level
- PL $3.38
- AUPH $7.89
- Resistance Level
- PL $3.59
- AUPH $8.38
- Average True Range (ATR)
- PL 0.16
- AUPH 0.24
- MACD
- PL 0.07
- AUPH 0.01
- Stochastic Oscillator
- PL 84.56
- AUPH 39.68
About PL Planet Labs PBC
Planet Labs PBC is an Earth-imaging company. The company provides daily satellite data that helps businesses, governments, researchers, and journalists understand the physical world and take action.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.